| Year |
Citation |
Score |
| 2020 |
Hacohen-Kleiman G, Moaraf S, Kapitansky O, Gozes I. Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain. Journal of Molecular Neuroscience : Mn. PMID 32926339 DOI: 10.1007/s12031-020-01700-x |
0.332 |
|
| 2020 |
Grigg I, Ivashko-Pachima Y, Hait TA, Korenková V, Touloumi O, Lagoudaki R, Van Dijck A, Marusic Z, Anicic M, Vukovic J, Kooy RF, Grigoriadis N, Gozes I. Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Translational Psychiatry. 10: 228. PMID 32661233 DOI: 10.1038/S41398-020-00904-4 |
0.322 |
|
| 2019 |
Sragovich S, Amram N, Yeheskel A, Gozes I. VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive and Effects. Frontiers in Cellular Neuroscience. 13: 589. PMID 31992971 DOI: 10.3389/fncel.2019.00589 |
0.366 |
|
| 2019 |
Ivashko-Pachima Y, Gozes I. A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP. Frontiers in Cellular Neuroscience. 13: 435. PMID 31632241 DOI: 10.3389/fncel.2019.00435 |
0.349 |
|
| 2019 |
Yang MH, Chen SC, Lin YF, Lee YC, Huang MY, Chen KC, Wu HY, Lin PC, Gozes I, Tyan YC. Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease. Journal of Food and Drug Analysis. 27: 551-564. PMID 30987727 DOI: 10.1016/J.Jfda.2018.11.009 |
0.33 |
|
| 2018 |
Ivashko-Pachima Y, Gozes I. NAP protects against Tau hyperphosphorylation through GSK3. Current Pharmaceutical Design. PMID 30417779 DOI: 10.2174/1381612824666181112105954 |
0.33 |
|
| 2018 |
Hacohen-Kleiman G, Sragovich S, Karmon G, Gao AYL, Grigg I, Pasmanik-Chor M, Le A, Korenková V, McKinney RA, Gozes I. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. The Journal of Clinical Investigation. PMID 30106381 DOI: 10.1172/JCI98199 |
0.316 |
|
| 2017 |
Gozes I. Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress. The Epma Journal. 8: 255-259. PMID 29021836 DOI: 10.1007/s13167-017-0110-x |
0.304 |
|
| 2017 |
Sragovich S, Merenlender-Wagner A, Gozes I. ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 28940660 DOI: 10.1002/bies.201700054 |
0.317 |
|
| 2017 |
Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Molecular Psychiatry. 22: 1335-1344. PMID 28115743 DOI: 10.1038/Mp.2016.255 |
0.389 |
|
| 2017 |
Gozes I. Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease. Journal of Neuroscience Research. 95: 652-660. PMID 27870441 DOI: 10.1002/jnr.23808 |
0.34 |
|
| 2016 |
Polanco MJ, Parodi S, Piol D, Stack C, Chivet M, Contestabile A, Miranda HC, Lievens PM, Espinoza S, Jochum T, Rocchi A, Grunseich C, Gainetdinov RR, Cato AC, Lieberman AP, ... ... Gozes I, et al. Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Science Translational Medicine. 8: 370ra181. PMID 28003546 DOI: 10.1126/scitranslmed.aaf9526 |
0.306 |
|
| 2016 |
Hadar A, Milanesi E, Squassina A, Niola P, Chillotti C, Pasmanik-Chor M, Yaron O, Martásek P, Rehavi M, Weissglas-Volkov D, Shomron N, Gozes I, Gurwitz D. RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. Translational Psychiatry. 6: e909. PMID 27701409 DOI: 10.1038/tp.2016.179 |
0.307 |
|
| 2016 |
Gozes I, Sragovich S, Schirer Y, Idan-Feldman A. D-SAL and NAP: Two Peptides Sharing a SIP Domain. Journal of Molecular Neuroscience : Mn. PMID 26816081 DOI: 10.1007/s12031-015-0701-8 |
0.324 |
|
| 2016 |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Gozes I, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356 |
0.494 |
|
| 2016 |
Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, Lagoudaki R, Grigoriadis NC, Giladi E, Yeheskel A, Pasmanik-Chor M, Jouroukhin Y, Gozes I. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Molecular Psychiatry. PMID 26782054 DOI: 10.1038/mp.2015.208 |
0.33 |
|
| 2015 |
Gozes I. Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer's disease. Springerplus. 4: L37. PMID 27386198 DOI: 10.1186/2193-1801-4-S1-L37 |
0.322 |
|
| 2015 |
Gozes I, Ivashko-Pachima Y. ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Frontiers in Aging Neuroscience. 7: 205. PMID 26578950 DOI: 10.3389/fnagi.2015.00205 |
0.343 |
|
| 2015 |
Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I. ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. Journal of Molecular Neuroscience : Mn. 57: 304-13. PMID 26315608 DOI: 10.1007/s12031-015-0640-4 |
0.334 |
|
| 2015 |
Kleiman GH, Barnea A, Gozes I. ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain. Peptides. PMID 25895853 DOI: 10.1016/J.Peptides.2015.04.008 |
0.325 |
|
| 2015 |
Gozes I, Yeheskel A, Pasmanik-Chor M. Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. Journal of Alzheimer's Disease : Jad. 45: 57-73. PMID 25428252 DOI: 10.3233/JAD-142490 |
0.303 |
|
| 2015 |
Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I. Autophagy has a key role in the pathophysiology of schizophrenia. Molecular Psychiatry. 20: 126-32. PMID 24365867 DOI: 10.1038/mp.2013.174 |
0.327 |
|
| 2014 |
Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacology Research & Perspectives. 2: e00065. PMID 25505609 DOI: 10.1002/Prp2.65 |
0.335 |
|
| 2014 |
Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, Grigoriadis NC, Gozes I. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy. 10: 2324-32. PMID 25484074 DOI: 10.4161/15548627.2014.984274 |
0.306 |
|
| 2014 |
Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Molecular Psychiatry. 19: 1115-24. PMID 25178163 DOI: 10.1038/mp.2014.97 |
0.344 |
|
| 2014 |
Magen I, Gozes I. Davunetide: Peptide therapeutic in neurological disorders. Current Medicinal Chemistry. 21: 2591-8. PMID 24533805 DOI: 10.2174/0929867321666140217124945 |
0.334 |
|
| 2014 |
Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). Journal of Alzheimer's Disease : Jad. 40: S23-36. PMID 24503616 DOI: 10.3233/JAD-131664 |
0.393 |
|
| 2014 |
Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. Plos One. 9: e87383. PMID 24489906 DOI: 10.1371/Journal.Pone.0087383 |
0.335 |
|
| 2014 |
Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S. NAP alpha-aminoisobutyric acid (IsoNAP). Journal of Molecular Neuroscience : Mn. 52: 1-9. PMID 24458740 DOI: 10.1007/s12031-013-0103-8 |
0.361 |
|
| 2014 |
Gozes I. Preventive, personalized medicine at the level of key regulatory proteins: updates on activity- dependent neuroprotective protein (ADNP) as a case study The Epma Journal. 5: 1-1. DOI: 10.1186/1878-5085-5-S1-A97 |
0.36 |
|
| 2013 |
Magen I, Gozes I. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides. 47: 489-95. PMID 24210139 DOI: 10.1016/j.npep.2013.10.011 |
0.303 |
|
| 2012 |
Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. Plos One. 7: e51458. PMID 23272107 DOI: 10.1371/journal.pone.0051458 |
0.381 |
|
| 2012 |
Gozes I. Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). Frontiers in Endocrinology. 3: 134. PMID 23162535 DOI: 10.3389/fendo.2012.00134 |
0.3 |
|
| 2012 |
Dresner E, Malishkevich A, Arviv C, Leibman Barak S, Alon S, Ofir R, Gothilf Y, Gozes I. Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. The Journal of Biological Chemistry. 287: 40173-85. PMID 23071114 DOI: 10.1074/jbc.M112.387027 |
0.343 |
|
| 2012 |
Jouroukhin Y, Ostritsky R, Gozes I. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. Journal of Molecular Neuroscience : Mn. 48: 597-602. PMID 22956189 DOI: 10.1007/s12031-012-9882-6 |
0.326 |
|
| 2012 |
Idan-Feldman A, Ostritsky R, Gozes I. Tau and caspase 3 as targets for neuroprotection. International Journal of Alzheimer's Disease. 2012: 493670. PMID 22693678 DOI: 10.1155/2012/493670 |
0.326 |
|
| 2012 |
Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatric Disease and Treatment. 8: 85-93. PMID 22347799 DOI: 10.2147/NDT.S12518 |
0.35 |
|
| 2012 |
Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. British Journal of Pharmacology. 166: 4-17. PMID 22289055 DOI: 10.1111/J.1476-5381.2012.01871.X |
0.344 |
|
| 2011 |
Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Current Pharmaceutical Design. 17: 3413-7. PMID 21902667 DOI: 10.2174/138161211798072553 |
0.355 |
|
| 2011 |
Shiryaev N, Pikman R, Giladi E, Gozes I. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Current Pharmaceutical Design. 17: 2603-12. PMID 21728979 DOI: 10.2174/138161211797416093 |
0.364 |
|
| 2011 |
Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Current Pharmaceutical Design. 17: 1040-4. PMID 21524250 DOI: 10.2174/138161211795589373 |
0.383 |
|
| 2011 |
Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neurosciences. 46: 597-606. PMID 21193046 DOI: 10.1016/J.Mcn.2010.12.011 |
0.327 |
|
| 2011 |
Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Neuroscience. 173: 156-68. PMID 21073926 DOI: 10.1016/j.neuroscience.2010.10.074 |
0.337 |
|
| 2011 |
Gozes I. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides. 32: 428-31. PMID 21050875 DOI: 10.1016/j.peptides.2010.10.030 |
0.322 |
|
| 2011 |
Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 21: 355-61. PMID 20598862 DOI: 10.1016/j.euroneuro.2010.06.004 |
0.301 |
|
| 2010 |
Gozes I. Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. The Epma Journal. 1: 305-16. PMID 23199066 DOI: 10.1007/s13167-010-0029-y |
0.311 |
|
| 2010 |
Gozes I. Tau pathology and future therapeutics. Current Alzheimer Research. 7: 685-96. PMID 20678069 DOI: 10.2174/156720510793611628 |
0.316 |
|
| 2010 |
Shiryaev N, Jouroukhin Y, Gozes I. 3R tau expression modifies behavior in transgenic mice. Journal of Neuroscience Research. 88: 2727-35. PMID 20544828 DOI: 10.1002/jnr.22431 |
0.3 |
|
| 2010 |
Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, Pozo D. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Journal of Molecular Neuroscience : Mn. 41: 114-20. PMID 19844808 DOI: 10.1007/s12031-009-9300-x |
0.369 |
|
| 2010 |
Gozes I, Schirer Y, Oz S. P3-428: Activity-dependent neuroprotective protein (ADNP) is regulated in the brains of mouse models of human tauopathies: Toward davunetide replacement therapy Alzheimer's & Dementia. 6: S578-S579. DOI: 10.1016/j.jalz.2010.05.1971 |
0.304 |
|
| 2009 |
Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Current Alzheimer Research. 6: 455-60. PMID 19874271 DOI: 10.2174/156720509789207895 |
0.321 |
|
| 2009 |
Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, Gozes I. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. Journal of Neurochemistry. 111: 1252-63. PMID 19799711 DOI: 10.1111/j.1471-4159.2009.06415.x |
0.347 |
|
| 2009 |
Zemlyak I, Sapolsky R, Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. European Journal of Pharmacology. 618: 9-14. PMID 19619522 DOI: 10.1016/j.ejphar.2009.07.013 |
0.306 |
|
| 2009 |
Zemlyak I, Sapolsky R, Gozes I. NAP protects against cyanide-related microtubule destruction. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 1411-6. PMID 19551468 DOI: 10.1007/s00702-009-0252-7 |
0.336 |
|
| 2009 |
Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiology of Disease. 34: 381-8. PMID 19264130 DOI: 10.1016/j.nbd.2009.02.011 |
0.314 |
|
| 2008 |
Gozes I, Divinski I, Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). Bmc Neuroscience. 9: S3. PMID 19091000 DOI: 10.1186/1471-2202-9-S3-S3 |
0.345 |
|
| 2008 |
Gozes I. VIP, from gene to behavior and back: summarizing my 25 years of research. Journal of Molecular Neuroscience : Mn. 36: 115-24. PMID 18607776 DOI: 10.1007/s12031-008-9105-3 |
0.345 |
|
| 2008 |
May V, Parsons RL, Gozes I. 8th international symposium on VIP, PACAP related peptides. Introduction. Journal of Molecular Neuroscience : Mn. 36: 1-2. PMID 18551257 DOI: 10.1007/s12031-008-9106-2 |
0.314 |
|
| 2008 |
Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. Journal of Molecular Neuroscience : Mn. 35: 127-41. PMID 18286385 DOI: 10.1007/s12031-007-9013-y |
0.348 |
|
| 2008 |
Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. The Journal of Pharmacology and Experimental Therapeutics. 325: 146-53. PMID 18199809 DOI: 10.1124/Jpet.107.130526 |
0.32 |
|
| 2008 |
Kushnir M, Dresner E, Mandel S, Gozes I. Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. Journal of Neurochemistry. 105: 537-45. PMID 18179478 DOI: 10.1111/j.1471-4159.2007.05173.x |
0.361 |
|
| 2008 |
Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. Journal of Peptide Science : An Official Publication of the European Peptide Society. 14: 321-8. PMID 17924396 DOI: 10.1002/Psc.932 |
0.347 |
|
| 2008 |
Matsuoka Y, Jouroukhin Y, Gozes I, Aisen PS. O4-04-03: A neuronal microtubule-interacting agent, nap, reduces hyperphosphorylated Tau and insoluble Tau, and enhances cognitive function in a transgenic mouse model of Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.529 |
0.301 |
|
| 2007 |
Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Current Alzheimer Research. 4: 507-9. PMID 18220512 DOI: 10.2174/156720507783018208 |
0.345 |
|
| 2007 |
Giladi E, Hill JM, Dresner E, Stack CM, Gozes I. Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. Journal of Molecular Neuroscience : Mn. 33: 278-83. PMID 17952637 DOI: 10.1007/s12031-007-9003-0 |
0.349 |
|
| 2007 |
Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. The Journal of Biological Chemistry. 282: 34448-56. PMID 17878164 DOI: 10.1074/jbc.M704756200 |
0.327 |
|
| 2007 |
Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, Gozes I. Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. Journal of Molecular Neuroscience : Mn. 31: 183-200. PMID 17726225 DOI: 10.1385/Jmn:31:03:185 |
0.357 |
|
| 2007 |
Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. The Journal of Pharmacology and Experimental Therapeutics. 323: 438-49. PMID 17720885 DOI: 10.1124/jpet.107.129551 |
0.342 |
|
| 2007 |
Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience : Mn. 31: 165-70. PMID 17478890 DOI: 10.1385/Jmn/31:02:165 |
0.342 |
|
| 2007 |
Busciglio J, Pelsman A, Helguera P, Ashur-Fabian O, Pinhasov A, Brenneman DE, Gozes I. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Current Pharmaceutical Design. 13: 1091-8. PMID 17430172 DOI: 10.2174/138161207780618957 |
0.315 |
|
| 2007 |
Gozes I. Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacology & Therapeutics. 114: 146-54. PMID 17363064 DOI: 10.1016/j.pharmthera.2007.01.004 |
0.398 |
|
| 2006 |
Dangoor D, Rubinraut S, Fridkin M, Gozes I. Novel extended and branched N-terminal analogs of VIP. Regulatory Peptides. 137: 42-9. PMID 16962672 DOI: 10.1016/J.Regpep.2006.02.010 |
0.323 |
|
| 2006 |
Pilzer I, Gozes I. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides. 27: 2867-76. PMID 16905223 DOI: 10.1016/j.peptides.2006.06.007 |
0.34 |
|
| 2006 |
Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. Journal of Neurochemistry. 98: 973-84. PMID 16893427 DOI: 10.1111/j.1471-4159.2006.03936.x |
0.358 |
|
| 2006 |
Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Annals of the New York Academy of Sciences. 1070: 500-6. PMID 16888216 DOI: 10.1196/annals.1317.069 |
0.327 |
|
| 2006 |
Pilzer I, Gozes I. A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. Annals of the New York Academy of Sciences. 1070: 484-90. PMID 16888214 DOI: 10.1196/annals.1317.067 |
0.338 |
|
| 2006 |
Gozes I, Spivak-Pohis I. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Current Alzheimer Research. 3: 197-9. PMID 16842095 DOI: 10.2174/156720506777632790 |
0.389 |
|
| 2006 |
Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Molecular and Cellular Endocrinology. 252: 148-53. PMID 16704895 DOI: 10.1016/j.mce.2006.03.029 |
0.36 |
|
| 2006 |
Holtser-Cochav M, Divinski I, Gozes I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. Journal of Molecular Neuroscience : Mn. 28: 303-7. PMID 16691018 DOI: 10.1385/JMN:28:3:303 |
0.331 |
|
| 2006 |
Sari Y, Gozes I. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Research Reviews. 52: 107-18. PMID 16488478 DOI: 10.1016/j.brainresrev.2006.01.004 |
0.332 |
|
| 2006 |
Mandel S, Gozes I. Revealing the role of activity dependent neuroprotective protein during embryogenesis Neuropeptides. 40: 430. DOI: 10.1016/j.npep.2006.09.018 |
0.305 |
|
| 2006 |
Gozes I, Shiryaev N, Jouroukhim Y, Pinhasov A, Ginzburg I, Rosenmann H. S4-04-03: Protecting the brain by nasal peptide delivery: From concept to the clinic Alzheimer's & Dementia. 2: S73-S73. DOI: 10.1016/J.Jalz.2006.05.286 |
0.334 |
|
| 2005 |
Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Cns Drug Reviews. 11: 353-68. PMID 16614735 DOI: 10.1111/J.1527-3458.2005.Tb00053.X |
0.369 |
|
| 2005 |
Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, Cohen-Armon M. PolyADP-ribosylation is involved in neurotrophic activity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 7420-8. PMID 16093393 DOI: 10.1523/JNEUROSCI.0333-05.2005 |
0.378 |
|
| 2005 |
Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides. 26: 1520-7. PMID 16042992 DOI: 10.1016/J.Peptides.2005.03.014 |
0.302 |
|
| 2005 |
Dangoor D, Giladi E, Fridkin M, Gozes I. Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides. 26: 2579-84. PMID 16023261 DOI: 10.1016/J.Peptides.2005.06.005 |
0.333 |
|
| 2005 |
Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Current Alzheimer Research. 2: 149-53. PMID 15974912 DOI: 10.2174/1567205053585873 |
0.358 |
|
| 2005 |
Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. Journal of Molecular Neuroscience : Mn. 25: 225-38. PMID 15800376 DOI: 10.1385/JMN:25:3:225 |
0.371 |
|
| 2005 |
Lagrèze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, Kirsch M. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Investigative Ophthalmology & Visual Science. 46: 933-8. PMID 15728550 DOI: 10.1167/iovs.04-0766 |
0.335 |
|
| 2005 |
Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, Gozes I. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neuroscience Letters. 373: 73-8. PMID 15555780 DOI: 10.1016/j.neulet.2004.09.077 |
0.338 |
|
| 2004 |
Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biology. 1: 193-9. PMID 16845437 DOI: 10.1017/S1740925X05000013 |
0.409 |
|
| 2004 |
Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. Journal of Alzheimer's Disease : Jad. 6: S37-41. PMID 15665412 DOI: 10.3233/Jad-2004-6S605 |
0.366 |
|
| 2004 |
Gozes I, Furman S. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Practice & Research. Clinical Endocrinology & Metabolism. 18: 623-40. PMID 15533779 DOI: 10.1016/j.beem.2004.08.006 |
0.344 |
|
| 2004 |
Zusev M, Gozes I. Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regulatory Peptides. 123: 33-41. PMID 15518891 DOI: 10.1016/j.regpep.2004.05.021 |
0.351 |
|
| 2004 |
Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, Gozes I. Brain injury-dependent expression of activity-dependent neuroprotective protein. Journal of Molecular Neuroscience : Mn. 24: 181-7. PMID 15456931 DOI: 10.1385/Jmn:24:2:181 |
0.305 |
|
| 2004 |
Gozes I, Steingart RA, Spier AD. NAP mechanisms of neuroprotection Journal of Molecular Neuroscience. 24: 67-72. PMID 15314252 DOI: 10.1385/Jmn:24:1:067 |
0.331 |
|
| 2004 |
Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze Neuroscience Letters. 361: 128-131. PMID 15135910 DOI: 10.1016/j.neulet.2003.12.005 |
0.309 |
|
| 2004 |
Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication Journal of Biological Chemistry. 279: 28531-28538. PMID 15123709 DOI: 10.1074/jbc.M403197200 |
0.343 |
|
| 2004 |
Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I. Protective peptides that are orally active and mechanistically nonchiral Journal of Pharmacology and Experimental Therapeutics. 309: 1190-1197. PMID 15007105 DOI: 10.1124/jpet.103.063891 |
0.348 |
|
| 2003 |
Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide Peptides. 24: 1413-1423. PMID 14706557 DOI: 10.1016/j.peptides.2003.08.005 |
0.35 |
|
| 2003 |
Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. From Vasoactive Intestinal Peptide (VIP) Through Activity-Dependent Neuroprotective Protein (ADNP) to NAP: A View of Neuroprotection and Cell Division Journal of Molecular Neuroscience. 20: 315-322. PMID 14501014 DOI: 10.1385/Jmn:20:3:315 |
0.418 |
|
| 2003 |
Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I. Activity-dependent neuroprotective protein: A novel gene essential for brain formation Developmental Brain Research. 144: 83-90. PMID 12888219 DOI: 10.1016/S0165-3806(03)00162-7 |
0.332 |
|
| 2003 |
Nowak JZ, Sedkowska P, Zawilska JB, Gozes I, Brenneman DE. Antagonism of VIP-stimulated cyclic AMP formation in chick brain Journal of Molecular Neuroscience. 20: 163-171. PMID 12794310 DOI: 10.1385/JMN:20:2:163 |
0.349 |
|
| 2002 |
Gozes I. Tau as a drug target in Alzheimer's disease Journal of Molecular Neuroscience. 19: 337-338. PMID 12540061 DOI: 10.1385/JMN:19:3:337 |
0.337 |
|
| 2002 |
Poggi SH, Vink J, Goodwin K, Hill JM, Brenneman DE, Pinhasov A, Gozes I, Spong CY. Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. American Journal of Obstetrics and Gynecology. 187: 973-6. PMID 12388989 DOI: 10.1067/mob.2002.127141 |
0.344 |
|
| 2002 |
Steingart RA, Heldenberg E, Pinhasov A, Brenneman DE, Fridkin M, Gozes I. A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes Life Sciences. 71: 2543-2552. PMID 12270759 DOI: 10.1016/S0024-3205(02)02082-9 |
0.306 |
|
| 2002 |
Wollman Y, Blumberg S, Spungin A, Brenneman DE, Fridkin M, Wollman J, Iaina A, Gozes I. The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase Regulatory Peptides. 108: 175-177. PMID 12220742 DOI: 10.1016/S0167-0115(02)00098-8 |
0.341 |
|
| 2002 |
Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE. NAP accelerates the performance of normal rats in the water maze. Journal of Molecular Neuroscience : Mn. 19: 167-70. PMID 12212775 DOI: 10.1007/s12031-002-0028-0 |
0.311 |
|
| 2002 |
Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death Stroke. 33: 1085-1092. PMID 11935065 DOI: 10.1161/01.Str.0000014207.05597.D7 |
0.335 |
|
| 2002 |
Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: Gene Atlas array analysis Journal of Molecular Neuroscience. 18: 37-45. PMID 11931348 DOI: 10.1385/Jmn:18:1-2:37 |
0.332 |
|
| 2002 |
Gozes I. Neuropeptides in the new millennium: Remembering friends who are no longer with us: Shmaryahu Blumberg and Noboru Yanaihara Journal of Molecular Neuroscience. 18: 1-3. DOI: 10.1385/JMN:18:1-2:1 |
0.335 |
|
| 2002 |
Gozes I, Furman S, Vulih I, Segal-Ruder Y, Fridkin M, Brenneman D. VIP, novel proteins and peptide-mediated neuronal survival European Neuropsychopharmacology. 12: 145-146. DOI: 10.1016/S0924-977X(02)80092-X |
0.364 |
|
| 2002 |
Gozes I, Spier AD. Peptides as drug candidates against Alzheimer's disease Drug Development Research. 56: 475-481. DOI: 10.1002/ddr.10103 |
0.383 |
|
| 2001 |
Sharma A, Walters J, Gozes Y, Fridkin M, Brenneman D, Gozes I, Moody TW. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells Journal of Molecular Neuroscience. 17: 331-339. PMID 11859929 DOI: 10.1385/Jmn:17:3:331 |
0.314 |
|
| 2001 |
Gozes I. Neuroprotective peptide drug delivery and development: Potential new therapeutics Trends in Neurosciences. 24: 700-705. PMID 11718874 DOI: 10.1016/S0166-2236(00)01931-7 |
0.376 |
|
| 2001 |
Ashur-Fabian O, Giladi E, Furman S, Steingart RA, Wollman Y, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neuroscience Letters. 307: 167-70. PMID 11438390 DOI: 10.1016/S0304-3940(01)01954-1 |
0.353 |
|
| 2001 |
Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I. Cloning and characterazation of the human activity-dependent neuroprotective protein Journal of Biological Chemistry. 276: 708-714. PMID 11013255 DOI: 10.1074/jbc.M007416200 |
0.325 |
|
| 2000 |
Sigalov E, Fridkin M, Brenneman DE, Gozes I. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells: A model for ischemic/hypoxic injury Journal of Molecular Neuroscience. 15: 147-154. PMID 11303779 DOI: 10.1385/Jmn:15:3:147 |
0.355 |
|
| 2000 |
Steingart RA, Solomon B, Brenneman DE, Fridkin M, Gozes I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress Journal of Molecular Neuroscience. 15: 137-145. PMID 11303778 DOI: 10.1385/Jmn:15:3:137 |
0.385 |
|
| 2000 |
Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE. A novel VIP responsive gene: Activity dependent neuroprotective protein Annals of the New York Academy of Sciences. 921: 115-118. PMID 11193814 DOI: 10.1111/J.1749-6632.2000.Tb06957.X |
0.377 |
|
| 2000 |
Zemlyak I, Furman S, Brenneman DE, Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regulatory Peptides. 96: 39-43. PMID 11102650 DOI: 10.1016/S0167-0115(00)00198-1 |
0.366 |
|
| 2000 |
Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I, Brenneman DE, McKay RD. A glia-derived signal regulating neuronal differentiation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 8012-20. PMID 11050122 DOI: 10.1523/Jneurosci.20-21-08012.2000 |
0.317 |
|
| 2000 |
Brenneman DE, Spong CY, Gozes I. Protective peptides derived from novel glial proteins Biochemical Society Transactions. 28: 452-455. PMID 10961938 DOI: 10.1042/Bst0280452 |
0.385 |
|
| 2000 |
Granoth R, Fridkin M, Gozes I. VIP and the potent analog, stearyl-Nle17-VIP, induce proliferation of keratinocytes Febs Letters. 475: 78-83. PMID 10858492 DOI: 10.1016/S0014-5793(00)01628-8 |
0.304 |
|
| 2000 |
Granoth R, Fridkin M, Rubinraut S, Gozes I. VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: The human keratinocyte as a model Febs Letters. 475: 71-77. PMID 10858491 DOI: 10.1016/S0014-5793(00)01629-X |
0.35 |
|
| 2000 |
Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection Journal of Molecular Neuroscience. 14: 61-68. PMID 10854037 DOI: 10.1385/Jmn:14:1-2:061 |
0.41 |
|
| 2000 |
White DM, Walker S, Brenneman DE, Gozes I. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor Brain Research. 868: 31-38. PMID 10841885 DOI: 10.1016/S0006-8993(00)02259-9 |
0.336 |
|
| 2000 |
Kim WK, Kan Y, Ganea D, Hart RP, Gozes I, Jonakait GM. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-α production in injured spinal cord and in activated microglia via a cAMP-dependent pathway Journal of Neuroscience. 20: 3622-3630. PMID 10804204 DOI: 10.1523/Jneurosci.20-10-03622.2000 |
0.312 |
|
| 2000 |
Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Research. 854: 257-62. PMID 10784133 DOI: 10.1016/S0006-8993(99)02375-6 |
0.543 |
|
| 2000 |
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Giladi E, Steingart RA, Furman S, Brenneman DE. A novel approach to Alzheimer's disease treatment: Intranasal application of neuroprotective peptide fragments Neurobiology of Aging. 21: 169. DOI: 10.1016/S0197-4580(00)82099-0 |
0.33 |
|
| 1999 |
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE. A novel signaling molecule for neuropeptide action: Activity-dependent neuroprotective protein Annals of the New York Academy of Sciences. 897: 125-135. PMID 10676441 DOI: 10.1111/j.1749-6632.1999.tb07884.x |
0.411 |
|
| 1999 |
Hill JM, Glazner GW, Lee SJ, Gozes I, Gressens P, Brenneman DE. Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. Annals of the New York Academy of Sciences. 897: 92-100. PMID 10676438 DOI: 10.1111/j.1749-6632.1999.tb07881.x |
0.303 |
|
| 1999 |
Brenneman DE, Hauser J, Phillips TM, Davidson A, Bassan M, Gozes I. Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism. Annals of the New York Academy of Sciences. 897: 17-26. PMID 10676432 DOI: 10.1111/J.1749-6632.1999.Tb07875.X |
0.387 |
|
| 1999 |
Glazner GW, Boland A, Dresse AE, Brenneman DE, Gozes I, Mattson MP. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death Journal of Neurochemistry. 73: 2341-2347. PMID 10582592 DOI: 10.1046/J.1471-4159.1999.0732341.X |
0.363 |
|
| 1999 |
Eilam R, Davidson A, Gozes I, Segal M. Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus Hippocampus. 9: 534-541. PMID 10560924 DOI: 10.1002/(SICI)1098-1063(1999)9:5<534::AID-HIPO7>3.0.CO;2-R |
0.385 |
|
| 1999 |
Ashur-Fabian O, Perl O, Lilling G, Fridkin M, Gozes I. SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival Peptides. 20: 629-633. PMID 10465516 DOI: 10.1016/S0196-9781(99)00017-0 |
0.316 |
|
| 1999 |
Hill JM, Lee SJ, Dibbern DA, Fridkin M, Gozes I, Brenneman DE. Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth. Neuroscience. 93: 783-91. PMID 10465461 DOI: 10.1016/S0306-4522(99)00155-4 |
0.364 |
|
| 1999 |
Glazner GW, Gressens P, Lee SJ, Gibney G, Gozes I, Gozes Y, Brenneman DE, Hill JM. Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. Anatomy and Embryology. 200: 65-71. PMID 10395007 DOI: 10.1007/s004290050260 |
0.351 |
|
| 1999 |
Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart RA, Atlas R, Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: A potential neuroprotective mechanism Neuroscience Letters. 264: 9-12. PMID 10320001 DOI: 10.1016/S0304-3940(99)00168-8 |
0.388 |
|
| 1999 |
Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S, Fridkin M. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design Proceedings of the National Academy of Sciences of the United States of America. 96: 4143-4148. PMID 10097177 DOI: 10.1073/Pnas.96.7.4143 |
0.383 |
|
| 1999 |
Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I. Complete sequence of a novel protein containing a femtomolar-activity- dependent neuroprotective peptide Journal of Neurochemistry. 72: 1283-1293. PMID 10037502 DOI: 10.1046/j.1471-4159.1999.0721283.x |
0.437 |
|
| 1998 |
Gozes I, Perl O, Zamostiano R, Rubinraut S, Fridkin M, Shochat L, Lewin LM. Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Annals of the New York Academy of Sciences. 865: 266-73. PMID 9928021 DOI: 10.1111/J.1749-6632.1998.Tb11187.X |
0.378 |
|
| 1998 |
Brenneman DE, Glazner G, Hill JM, Hauser J, Davidson A, Gozes I. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Annals of the New York Academy of Sciences. 865: 207-12. PMID 9928014 DOI: 10.1111/j.1749-6632.1998.tb11180.x |
0.41 |
|
| 1998 |
Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun Journal of Biological Chemistry. 273: 31427-31436. PMID 9813054 DOI: 10.1074/jbc.273.47.31427 |
0.36 |
|
| 1998 |
Bassan M, Zamostiano R, Giladi E, Davidson A, Wollman Y, Pitman J, Hauser J, Brenneman DE, Gozes I. The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line. Neuroscience Letters. 250: 37-40. PMID 9696060 DOI: 10.1016/S0304-3940(98)00428-5 |
0.342 |
|
| 1998 |
Zupan V, Hill JM, Brenneman DE, Gozes I, Fridkin M, Robberecht P, Evrard P, Gressens P. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. Journal of Neurochemistry. 70: 2165-73. PMID 9572304 DOI: 10.1046/J.1471-4159.1998.70052165.X |
0.356 |
|
| 1998 |
Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M. Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochemical Research. 23: 689-93. PMID 9566607 DOI: 10.1023/A:1022494907001 |
0.324 |
|
| 1998 |
Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. Journal of Molecular Neuroscience : Mn. 9: 211-22. PMID 9481622 DOI: 10.1007/BF02800503 |
0.351 |
|
| 1997 |
Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. Journal of Neurobiology. 33: 329-42. PMID 9298769 DOI: 10.1002/(Sici)1097-4695(199709)33:3<329::Aid-Neu10>3.0.Co;2-A |
0.388 |
|
| 1997 |
Chew LJ, Burke ZD, Morgan H, Gozes I, Murphy D, Carter DA. Transcription of the vasoactive intestinal peptide gene in response to glucocorticoids: Differential regulation of alternative transcripts is modulated by a labile protein in rat anterior pituitary Molecular and Cellular Endocrinology. 130: 83-91. PMID 9220024 DOI: 10.1016/S0303-7207(97)00076-2 |
0.347 |
|
| 1997 |
Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. The Journal of Clinical Investigation. 100: 390-7. PMID 9218516 DOI: 10.1172/Jci119545 |
0.369 |
|
| 1997 |
Dibbern DA, Glazner GW, Gozes I, Brenneman DE, Hill JM. Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. The Journal of Clinical Investigation. 99: 2837-41. PMID 9185505 DOI: 10.1172/JCI119476 |
0.341 |
|
| 1997 |
Brenneman DE, Phillips TM, Festoff BW, Gozes I. Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide Annals of the New York Academy of Sciences. 814: 167-173. PMID 9160969 DOI: 10.1111/j.1749-6632.1997.tb46155.x |
0.35 |
|
| 1997 |
Gozes I, Davidson A, Gozes Y, Mascolo R, Barth R, Warren D, Hauser J, Brenneman DE. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Research. Developmental Brain Research. 99: 167-75. PMID 9125470 DOI: 10.1016/S0165-3806(96)00215-5 |
0.347 |
|
| 1997 |
Gozes I, Bassan M, Zamostiano R, Davidson A, Perl O, Bassan H, Blat C, Giladi E, Gibney G, Glazner G, Brenneman D. A femtomolar-acting activity-dependent neuroprotective protein (ADNP) Neuroscience Letters. 237: S21. DOI: 10.1016/S0304-3940(97)90086-0 |
0.305 |
|
| 1997 |
Giladi E, Davidson A, Bachar M, Bardea A, Rubinraut S, Fridkin M, Brenneman D, Gozes I. Protection against developmental and learning impairments in apolipoprotein e-deficient mice by activity-dependent femtomolar-acting peptides Neuroscience Letters. 237: S19. DOI: 10.1016/S0304-3940(97)90077-X |
0.312 |
|
| 1996 |
Brenneman DE, Hill JM, Gozes I, Phillips TM. Vasoactive intestinal peptide releases interleukin-1 from astrocytes. Annals of the New York Academy of Sciences. 805: 280-7; discussion 28. PMID 8993410 DOI: 10.1111/j.1749-6632.1996.tb17490.x |
0.313 |
|
| 1996 |
Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? Journal of Molecular Neuroscience. 7: 235-244. PMID 8968945 DOI: 10.1007/Bf02737061 |
0.411 |
|
| 1996 |
Davidson A, Moody TW, Gozes I. Regulation of VIP gene expression in general: Human lung cancer cells in particular Journal of Molecular Neuroscience. 7: 99-110. PMID 8873894 DOI: 10.1007/Bf02736790 |
0.303 |
|
| 1996 |
Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. The Journal of Clinical Investigation. 97: 2299-307. PMID 8636410 DOI: 10.1172/JCI118672 |
0.398 |
|
| 1996 |
Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE. Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide Proceedings of the National Academy of Sciences of the United States of America. 93: 427-432. PMID 8552653 DOI: 10.1073/Pnas.93.1.427 |
0.385 |
|
| 1995 |
Gozes I, Fridkin M, Brenneman DE. A VIP hybrid antagonist: From developmental neurobiology to clinical applications Cellular and Molecular Neurobiology. 15: 675-687. PMID 8719036 DOI: 10.1007/Bf02071131 |
0.354 |
|
| 1995 |
Hill JM, Mervis RF, Politi J, McCune SK, Gozes I, Fridkin M, Brenneman DE. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Annals of the New York Academy of Sciences. 739: 211-25. PMID 7832475 DOI: 10.1111/J.1749-6632.1994.Tb19823.X |
0.313 |
|
| 1995 |
Lilling G, Wollman Y, Goldstein MN, Rubinraut S, Fridkin M, Brenneman DE, Gozes I. Inhibition of human neuroblastoma growth by a specific VIP antagonist. Journal of Molecular Neuroscience : Mn. 5: 231-9. PMID 7577366 DOI: 10.1007/Bf02736724 |
0.339 |
|
| 1994 |
Wollman Y, Lilling G, Goldstein MN, Fridkin M, Gozes I. Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells. Brain Research. 624: 339-41. PMID 8252411 DOI: 10.1016/0006-8993(93)90100-2 |
0.369 |
|
| 1994 |
Gozes I, Avidor R, Giladi E, Shani Y, McEwen BS, Dussaillant M, Rostene W. Adrenalectomy decreases vasoactive intestinal peptide mRNA levels in the rat suprachiasmatic nucleus. Neuroscience Letters. 167: 24-8. PMID 8177525 DOI: 10.1016/0304-3940(94)91019-7 |
0.318 |
|
| 1994 |
Gozes I, Reshef A, Salah D, Rubinraut S, Fridkin M. Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment Endocrinology. 134: 2121-2125. PMID 8156912 DOI: 10.1210/Endo.134.5.8156912 |
0.318 |
|
| 1994 |
Glazer R, Gozes I. Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining. Brain Research. 644: 164-7. PMID 8032943 DOI: 10.1016/0006-8993(94)90360-3 |
0.32 |
|
| 1994 |
Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M, Brenneman DE. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. The Journal of Clinical Investigation. 94: 2020-7. PMID 7962548 DOI: 10.1172/Jci117555 |
0.383 |
|
| 1993 |
Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos Nature. 362: 155-158. PMID 8383805 DOI: 10.1038/362155A0 |
0.331 |
|
| 1993 |
Gozes I, Glowa J, Brenneman DE, McCune SK, Lee E, Westphal H. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene Journal of Molecular Neuroscience. 4: 185-193. PMID 8292491 DOI: 10.1007/BF02782501 |
0.323 |
|
| 1992 |
Brenneman DE, Schultzberg M, Bartfai T, Gozes I. Cytokine Regulation of Neuronal Survival Journal of Neurochemistry. 58: 454-460. PMID 1729393 DOI: 10.1111/J.1471-4159.1992.Tb09743.X |
0.315 |
|
| 1992 |
Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, Hill JM. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist Brain Research. 570: 49-53. PMID 1617429 DOI: 10.1016/0006-8993(92)90562-N |
0.306 |
|
| 1992 |
Gozes I, Fridkin M. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model Journal of Clinical Investigation. 90: 810-814. PMID 1522236 DOI: 10.1097/00006254-199303000-00022 |
0.339 |
|
| 1992 |
Dussaillant M, Sarrieau A, Gozes I, Berod A, Rostene W. Distribution of cells expressing vasoactive intestinal peptide/peptide histidine isoleucine-amide precursor messenger RNA in the rat brain. Neuroscience. 50: 519-30. PMID 1436503 DOI: 10.1016/0306-4522(92)90444-7 |
0.372 |
|
| 1991 |
Agoston DV, Eiden LE, Brenneman DE, Gozes I. Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures Molecular Brain Research. 10: 235-240. PMID 1715967 DOI: 10.1016/0169-328X(91)90066-7 |
0.308 |
|
| 1990 |
Gozes I, Brenneman DE. VIP: molecular biology and neurobiological function. Molecular Neurobiology. 3: 201-36. PMID 2698176 DOI: 10.1007/BF02740606 |
0.403 |
|
| 1989 |
Gozes I, Avidor R, Biegon A, Baldino F. Lactation elevates vasoactive intestinal peptide messenger ribonucleic acid in rat suprachiasmatic nucleus. Endocrinology. 124: 181-6. PMID 2909364 DOI: 10.1210/ENDO-124-1-181 |
0.36 |
|
| 1989 |
Baldino F, Fitzpatrick-McElligott S, O'Kane TM, Gozes I. Hormonal regulation of somatostatin messenger RNA. Synapse (New York, N.Y.). 2: 317-25. PMID 2905534 DOI: 10.1002/SYN.890020322 |
0.31 |
|
| 1989 |
Gozes I, Werner H, Fawzi M, Abdelatty A, Shani Y, Fridkin M, Koch Y. Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience : Mn. 1: 55-61. PMID 2642065 DOI: 10.1007/Bf02896857 |
0.315 |
|
| 1989 |
Avidor R, Eilam R, Malach R, Gozes I. VIP-mRNA is increased in hypertensive rats. Brain Research. 503: 304-7. PMID 2605522 DOI: 10.1016/0006-8993(89)91679-X |
0.305 |
|
| 1989 |
Gozes I, Meltzer E, Rubinrout S, Brenneman DE, Fridkin M. Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist Endocrinology. 125: 2945-2949. PMID 2583049 DOI: 10.1210/Endo-125-6-2945 |
0.346 |
|
| 1989 |
Gozes I, Avidor R, Giladi E, Levi-Holtzman R, Shani Y, Malach R. Vasoactive intestinal peptide (VIP) gene expression in the suprachiasmatic nucleus-the biological pacemaker Regulatory Peptides. 26: 159. DOI: 10.1016/0167-0115(89)90042-6 |
0.334 |
|
| 1988 |
Gozes I, Schächter P, Shani Y, Giladi E. Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology. 47: 27-31. PMID 3340270 DOI: 10.1159/000124886 |
0.356 |
|
| 1988 |
Gozes I. Biosynthesis and regulation of expression. The vasoactive intestinal peptide gene. Annals of the New York Academy of Sciences. 527: 77-87. PMID 3291702 DOI: 10.1111/J.1749-6632.1988.TB26974.X |
0.335 |
|
| 1987 |
Boss BD, Gozes I, Cowan WM. The survival of dentate gyrus neurons in dissociated culture. Brain Research. 433: 199-218. PMID 3319046 DOI: 10.1016/0165-3806(87)90024-1 |
0.303 |
|
| 1987 |
Gozes I, Nakai H, Byers M, Avidor R, Weinstein Y, Shani Y, Shows TB. Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24. Somatic Cell and Molecular Genetics. 13: 305-13. PMID 2842874 DOI: 10.1007/BF01534924 |
0.309 |
|
| 1987 |
Gozes I, Shani Y, Rostène WH. Developmental expression of the VIP-gene in brain and intestine. Brain Research. 388: 137-48. PMID 2441796 DOI: 10.1016/S0006-8993(87)80007-0 |
0.348 |
|
| 1987 |
Gozes I, Giladi E, Shani Y. Vasoactive intestinal peptide gene: putative mechanism of information storage at the RNA level. Journal of Neurochemistry. 48: 1136-1141. PMID 2434617 DOI: 10.1111/J.1471-4159.1987.Tb05638.X |
0.306 |
|
| 1986 |
Gozes I, Tsafriri A. Detection of vasoactive intestinal peptide-encoding messenger ribonucleic acid in the rat ovaries. Endocrinology. 119: 2606-10. PMID 3780542 DOI: 10.1210/ENDO-119-6-2606 |
0.326 |
|
| 1986 |
Gozes I, Shani Y. Hypothalamic vasoactive intestinal peptide messenger ribonucleic acid is increased in lactating rats. Endocrinology. 119: 2497-2501. PMID 3780537 DOI: 10.1210/Endo-119-6-2497 |
0.336 |
|
| 1986 |
Gozes I, Bodner M, Shani Y, Fridkin M. Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor. Peptides. 7: 1-6. PMID 3748844 DOI: 10.1016/0196-9781(86)90156-7 |
0.308 |
|
| 1985 |
Werner H, Koch Y, Fridkin M, Fahrenkrug J, Gozes I. High levels of vasoactive intestinal peptide in human milk. Biochemical and Biophysical Research Communications. 133: 228-32. PMID 4074363 DOI: 10.1016/0006-291X(85)91865-0 |
0.319 |
|
| 1985 |
Bodner M, Fridkin M, Gozes I. Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome Proceedings of the National Academy of Sciences of the United States of America. 82: 3548-3551. PMID 2987932 DOI: 10.1073/Pnas.82.11.3548 |
0.303 |
|
| 1985 |
Gozes I, Bodner M, Shani Y, Avidor R, Brill E, Fridkin M. Structure and expression of the vasoactive intestinal peptide (VIP) gene Regulatory Peptides. 10: S14. DOI: 10.1016/0167-0115(85)90304-0 |
0.326 |
|
| 1984 |
Gozes I, Bodner M, Shani Y, Fridkin M. Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides Journal of Cellular Biochemistry. 26: 147-156. PMID 6526855 DOI: 10.1002/Jcb.240260303 |
0.346 |
|
| 1982 |
Gozes I. Tubulin In The Nervous System Neurochemistry International. 4: 101-120. PMID 20487857 DOI: 10.1016/0197-0186(82)90003-1 |
0.305 |
|
| 1981 |
Gozes I, Sweadner KJ. Multiple tubulin forms are expressed by a single neurone. Nature. 294: 477-480. PMID 7312039 DOI: 10.1038/294477A0 |
0.328 |
|
| 1981 |
Gozes I, Cronin BL, Moskowitz MA. Protein synthesis in rat brain microvessels decreases with aging. Journal of Neurochemistry. 36: 1311-5. PMID 7205273 DOI: 10.1111/j.1471-4159.1981.tb01738.x |
0.307 |
|
| 1979 |
Walker MD, Negreanu V, Gozes I, Kaye AM. Identification of the 'estrogen-induced protein' in uterus and brain of untreated immature rats Febs Letters. 98: 187-191. PMID 428535 DOI: 10.1016/0014-5793(79)80180-5 |
0.309 |
|
| 1978 |
Gozes I, Littauer UZ. Tubulin microheterogeneity increases with rat brain maturation. Nature. 276: 411-3. PMID 714168 DOI: 10.1038/276411A0 |
0.301 |
|
| 1977 |
Schmitt H, Gozes I, Littauer UZ. Decrease in levels and rates of synthesis of tubulin and actin in developing rat brain. Brain Research. 121: 327-42. PMID 832166 DOI: 10.1016/0006-8993(77)90155-X |
0.308 |
|
| 1976 |
Littauer UZ, Schmitt H, Gozes I. Properties and synthesis of tubulin in neuroblastoma cells. Journal of the National Cancer Institute. 57: 647-51. PMID 789906 DOI: 10.1093/Jnci/57.3.647 |
0.318 |
|
| 1975 |
Gozes I, Schmitt H, Littauer UZ. Translation in vitro of rat brain messenger RNA coding for tubulin and actin. Proceedings of the National Academy of Sciences of the United States of America. 72: 701-5. PMID 1054847 DOI: 10.1073/Pnas.72.2.701 |
0.301 |
|
| Show low-probability matches. |